Insider Trading November 16, 2026 08:00 AM

CorMedix CEO Joseph Todisco Purchases $391,200 in Company Shares

The insider buy comes as the stock trades near its 52-week low, following a double-digit decline over the past week.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
CRMD

CorMedix Inc. (NASDAQ:CRMD) Chief Executive Officer and Director Joseph Todisco acquired 80,000 shares of company common stock on November 13, 2026, at a weighted average price of $4.89, for a total value of $391,200. The purchase was executed in multiple trades with prices ranging from $4.85 to $5.00 per share. The transaction occurred as CorMedix shares, currently at $4.66, hover near their 52-week low of $4.65 after falling nearly 15% over the past week. Following the acquisition, Todisco directly beneficially owns 854,749 shares. In other recent news, CorMedix reported third-quarter revenue of $54.5 million, surpassing Wall Street expectations but down from $104.3 million a year earlier. The company posted a wider-than-expected net loss of $0.19 per share, against analysts' estimates of a $0.10 loss, attributed to adjustments in the reimbursement setting for its flagship product, DefenCath. Oppenheimer subsequently adjusted its price target for CorMedix shares to $13 from $15, maintaining an Outperform rating, and revised its valuation model by removing TPN and incorporating Heron, which adds commercial revenue and leverages existing infrastructure.

CorMedix CEO Joseph Todisco Purchases $391,200 in Company Shares
CRMD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO Joseph Todisco bought 80,000 shares at a weighted average price of $4.89, totaling $391,200, as the stock trades near its 52-week low.
  • The purchase increases Todisco's direct beneficial ownership to 854,749 shares.
  • CorMedix reported Q3 revenue of $54.5 million, beating expectations but down year-over-year, with a wider-than-expected net loss attributed to DefenCath reimbursement adjustments.
  • Oppenheimer lowered its price target to $13 from $15 while maintaining an Outperform rating, revising its model to remove TPN and incorporate Heron.

CorMedix Inc. (NASDAQ:CRMD) disclosed that its Chief Executive Officer and Director, Joseph Todisco, acquired 80,000 shares of the company's common stock on November 13, 2026. The total value of the transaction amounted to $391,200.

The shares were purchased at a weighted average price of $4.89. The transactions were executed in multiple trades with prices ranging from $4.85 to $5.00 per share. The timing of this insider purchase is notable, as the stock is currently trading at $4.66, near its 52-week low of $4.65, after declining nearly 15% over the past week. According to InvestingPro analysis, CRMD appears undervalued at current levels, with the stock trading at a P/E ratio of just 6.62. Investors can access the full Fair Value analysis and 13 additional ProTips on InvestingPro.

Following this acquisition, Mr. Todisco directly beneficially owns 854,749 shares of CorMedix common stock.

In other recent news, CorMedix reported third-quarter revenue that surpassed Wall Street expectations, reaching $54.5 million. This marks a decrease from $104.3 million a year earlier. Despite the revenue beat, the company experienced a wider-than-expected net loss of $0.19 per share, against analysts' estimates of a $0.10 loss. The loss was attributed to adjustments in the reimbursement setting for its flagship product, DefenCath. Following these results, Oppenheimer adjusted its price target for CorMedix shares to $13 from $15, maintaining an Outperform rating. The firm revised its valuation model by removing TPN and incorporating Heron, which adds commercial revenue and leverages existing infrastructure. These developments reflect CorMedix's ongoing adjustments and strategic shifts in the market.

The insider purchase comes at a time when CorMedix shares are under pressure, trading near their 52-week low. The stock's decline of nearly 15% over the past week has raised questions about the company's near-term prospects. However, the CEO's decision to increase his stake could be interpreted as a signal of confidence in the company's long-term strategy, particularly following the recent reimbursement adjustments for DefenCath.

CorMedix's third-quarter results highlighted the impact of reimbursement changes on its financial performance. While revenue exceeded expectations, the wider net loss underscores the challenges the company faces in navigating the evolving reimbursement landscape. Oppenheimer's revised price target and maintained Outperform rating suggest that the firm sees potential in CorMedix's strategic shifts, including the incorporation of Heron and the removal of TPN from its valuation model.

Investors will continue to monitor insider activity and analyst revisions for further clues about CorMedix's direction. The company's ability to manage reimbursement pressures and execute on its strategic initiatives will be key factors in determining its future performance.

Risks

  • The stock is trading near its 52-week low and has declined nearly 15% over the past week, indicating negative market sentiment and potential further volatility.
  • The wider-than-expected net loss and reimbursement adjustments for DefenCath could continue to pressure financial results and investor confidence.
  • Analyst price target reductions, such as Oppenheimer's cut to $13 from $15, may reflect broader concerns about the company's valuation and growth prospects.

More from Insider Trading

Hinge Health Co-Founder Mecklenburg Offloads $24.48M in Shares Near 52-Week High Nov 16, 2026 IBEX People Chief Offloads $100K in Stock as Shares Climb to Near 52-Week High Nov 15, 2026 Marqeta CAO Sumner Crystal Offloads 1,250 Shares in $20,487 Open-Market Sale Nov 15, 2026 Wayfair Director Conine Offloads $7.13 Million in Stock Under Pre-Arranged Plan Nov 15, 2026 IBEX Legal Chief Offloads $395,727 in Shares as Stock Soars to Near 52-Week High Nov 15, 2026